Cytokeratin 19 (CK19) is an acidic protein of 40 kDa that is part of the cytoskeleton of epithelial cells. It is highly expressed by all epithelial cells and represents a useful indicator of epithelial differentiation. The soluble fragment of CK19 (CYFRA 21–1) can be a useful circulating tumor marker and can be detected in the serum of cancer patients. The development of metastasis in patients with cancer of epithelial origin is due to the migration of tumor cells from the original tumor to distant organs. In order to detect micrometastasis in patients with breast cancer, we evaluated and compared CK19 gene expression using RT-PCR in blood samples collected from 80 healthy women and 80 patients with localized or metastatic breast cancer. The concentration of the soluble CK19 fragment CYFRA 21–1 was measured in serum of all study subjects by radioimmunoassay employing specific monoclonal antibodies. The relationship between the expression of this molecular marker and clinical stage, tumor differentiation and CK19 mRNA transcripts was investigated. We found that CK19 mRNA expression in blood (as a direct index of the presence of circulating tumor cells) was not correlated with CYFRA 21–1.
ParkinD.M., BrayF., FerlayJ., PisaniP.. Estimating the world cancer burden: Globocan 2000.Int J Cancer2001; 94: 153–6.
2.
Charef-HamzaS., TrimecheM., ZiadiM., AmaraK., GaddasN., MokniM.. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.Cancer Lett2005; 224: 185–91.
StieberP., DienemannH., HasholznerU.. Comparison of CYFRA 21–1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.Int J Biol Markers1994; 9: 82–8.
5.
DoweckI., BarakM., GreenbergE.. CYFRA 21–1. A new potential tumor marker for squamous cell carcinoma of head and neck.Arch Otolaryngol Head Neck Surg1995; 121: 177–81.
6.
NakataB., ChungY.S., KatoY.. Clinical significance of serum CYFRA 21–1 in gastric cancer.Br J Cancer1996; 73: 1529–32.
7.
HasholznerU., BaumgartnerL., StieberP., MeierW., HofmannK., Fateh-MoghadamA.. Significance of the tumor markers CA 125 II, CA 72–4, CASA and CYFRA 21–1 in ovarian carcinoma.Anticancer Res1994; 14: 2743–6.
8.
NakataB., OgawaY., IshikawaT.. Serum CYFRA 21–1 is one of the most reliable tumor markers for breast carcinoma.Cancer2000; 89: 1285–90.
9.
TheyerG., DurerA., TheyerU.. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21–1 in prostate cancer patients under intermittent androgen suppression therapy.Prostate1999, 41: 71–7.
10.
GiovanellaL., CerianiL., GhelfoA., MaffioliM.. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland.Int J Biol Markers2008; 23: 54–7.
11.
Fernandez-GomezJ., Rodríguez-MartínezJ.J., BarmadahS.E.. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.Eur Urol2007; 51: 1267–74.
12.
XenidisN., VlachonikolisI., MavroudisD.. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.Ann Oncol2003; 14: 849–55.
13.
CoteR.J., RosenP.P., LesserM.L.. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.J Clin Oncol1991; 9: 1749–56.
14.
DielI.J., KaufmannM., CostaS.D.. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status.J Natl Cancer Inst1996; 88: 1652–8.
15.
SchoenfeldA., KrugerK.H., GommJ.. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19.Eur J Cancer1997; 33: 854–61.
16.
DattaY.H., AdamsP.T., DrobyskiW.R., EthierS.P., TerryV.H., RothM.S.. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction.J Clin Oncol1994; 12: 475–82.
17.
KrismannM., TodtB., SchroderJ.. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.J Clin Oncol1995; 13: 2769–75.
18.
BeroisN., VarangotM., OsinagaE.. Detection of rare human breast cancer cells: Comparison of an immunomagnetic separation method with immunochemistry and RT-PCR.Anticancer Res1997; 17: 2639–46.
19.
PeckK., SherY.P., ShihJ.Y.. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients.Cancer Res1998; 58: 2761–5.
20.
KoY., GrunewaldE., TotzkeG.. High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: a model for the analysis of illegitimate gene expression.Oncology2001; 59: 81–8.
21.
MolinaR., AgustiC., FilellaX.. Study of a new tumor marker, CYFRA 21–1, in malignant and non malignant diseases.Tumour Biol1994; 15: 318–25.
22.
RodriguezC.A., CruzJ.J., MartinT., GomezA., OlaverriA., HernandezM.. Serum CYFRA 21–1 is one of the most reliable tumor markers for breast carcinoma.Cancer2002; 95: 670–1.
23.
BrotherickI., RobsonC.N., BrowellD.A.. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression.Cytometry1998; 32: 301–8.
24.
PujolJ.L., GrenierJ., DauresJ.P., DaverA., PujolH., MichelF.B.. Serum fragments of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer.Cancer Res1993; 53: 61–6.
25.
NakataB., TakashimaT., OgawaY., IshikawaT., HirakawaK.. Serum CYFRA 21–1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.Br J Cancer2004; 91: 873–8.
26.
GiovanellaL., CerianiL., GiardinaG., BardelliD., TanziF., GaranciniS.. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).Clin Chem Lab Med2002; 40: 298–303.
